MaaT Pharma SA

DB:4RD Stock Report

Market Cap: €52.0m

MaaT Pharma Management

Management criteria checks 3/4

MaaT Pharma's CEO is Herve Affagard, appointed in Dec 2014, has a tenure of 11.5 years. total yearly compensation is €982.94K, comprised of 30.5% salary and 69.5% bonuses, including company stock and options. directly owns 1.41% of the company’s shares, worth €734.64K. The average tenure of the management team and the board of directors is 2.3 years and 6.1 years respectively.

Key information

Herve Affagard

Chief executive officer

€982.9k

Total compensation

CEO salary percentage30.52%
CEO tenure11.5yrs
CEO ownership1.4%
Management average tenure2.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Herve Affagard's remuneration changed compared to MaaT Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-€31m

Sep 30 2025n/an/a

-€31m

Jun 30 2025n/an/a

-€31m

Mar 31 2025n/an/a

-€30m

Dec 31 2024€983k€300k

-€29m

Sep 30 2024n/an/a

-€27m

Jun 30 2024n/an/a

-€24m

Mar 31 2024n/an/a

-€22m

Dec 31 2023€2m€300k

-€20m

Sep 30 2023n/an/a

-€17m

Jun 30 2023n/an/a

-€15m

Mar 31 2023n/an/a

-€14m

Dec 31 2022€734k€292k

-€14m

Sep 30 2022n/an/a

-€13m

Jun 30 2022n/an/a

-€12m

Mar 31 2022n/an/a

-€11m

Dec 31 2021€279k€198k

-€9m

Sep 30 2021n/an/a

-€8m

Jun 30 2021n/an/a

-€7m

Mar 31 2021n/an/a

-€6m

Dec 31 2020€831k€233k

-€5m

Compensation vs Market: Herve's total compensation ($USD1.13M) is above average for companies of similar size in the German market ($USD440.72K).

Compensation vs Earnings: Herve's compensation has been consistent with company performance over the past year.

CEO

Herve Affagard (52 yo)

11.5yrs
Tenure
€982,944
Compensation

Mr. Herve Affagard is Co-Founder at MaaT Pharma SA and is its CEO since December 3, 2014. He is Director at MaaT Pharma SA since 2014.

Leadership Team

NamePositionTenureCompensationOwnership
Herve Affagard
CEO, Co-Founder & Director11.5yrs€982.94k1.41%
€ 734.6k
Joel Dore
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Pierre Rimbaud
Co-Founderno datano datano data
Eric Soyer
Chief Financial Officer1.6yrsno datano data
Carole Schwintner
Technology Director & Chief Technology Officerno datano datano data
Sheri Simmons
Acting Chief Scientific Officerno datano datano data
Guilhaume Debroas
Head of Investor Relations3yrsno datano data
Frederic Fasano
Chief Strategy & Corporate Development Officerless than a yearno datano data
Sian Crouzet
Chief of Staff1.6yrsno datano data
Emilie Plantamura
Deputy Chief Medical Officer3yrsno datano data
2.3yrs
Average Tenure
58yo
Average Age

Experienced Management: 4RD's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Herve Affagard
CEO, Co-Founder & Director12.4yrs€982.94k1.41%
€ 734.6k
Joel Dore
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Isabelle de Cremoux
Representative Director12.4yrsno datano data
Claude Bertrand
Independent Non-Executive Director5.9yrs€35.00kno data
Muriel Prudent
Representative Directorno datano datano data
Jean Volatier
Independent Non Executive Director5.4yrs€45.00kno data
Mohamad Mohty
Member of Advisory Board (Medical Hematology – Oncology Advisor)no datano datano data
Robert Jenq
Member of Scientific Advisory Board6.1yrsno datano data
Ernst Holler
Chair of Scientific Advisory Board6.1yrsno datano data
Florent Malard
Member of Scientific Advisory Board6.1yrsno datano data
Robert Zeiser
Member of Scientific Advisory Board6.1yrsno datano data
Jean-Marie Lefevre
Chairman of the Board10.4yrsno datano data
6.1yrs
Average Tenure
58.5yo
Average Age

Experienced Board: 4RD's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 08:38
End of Day Share Price 2026/06/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MaaT Pharma SA is covered by 4 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christian OrqueraFirst Berlin Equity Research GmbH
Jacob MekhaelKBC Securities NV
Mohamed KaabouniPortzamparc BNP Paribas